Sale

Contraceptive Drugs Market

Global Contraceptive Drugs Market Share, Size, Growth, Analysis: By Product Type: Contraceptive Drugs; By Route of Administration: Oral, Parentals, Topicals, Others; By Therapy Type: Monotherapy, Combined Contraceptives; By Age Group: 15-45 Years, Above 45 Years; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032

Global Contraceptive Drugs Market Outlook

The global contraceptive drugs market size attained a value of USD 18.64 billion in 2023. The market is further expected to grow at a CAGR of 7% during the forecast period of 2024-2032 to attain a value of USD 34.33 billion by 2032. The growth of the market is driven by the increasing awareness and acceptance of contraceptive drugs.

 

Global Contraceptive Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Availability of Free and Subsidised Contraceptive Drugs Driving the Market Growth

As governments are increasingly attempting to enhance the quality of life of their citizens, they are increasingly providing free and subsidised contraceptive drugs, thereby driving the growth of the market. Moreover, governments of low-and-middle-income companies are launching various favourable initiatives like advertisements to promote contraceptive drugs among their population.

For instance, in July 2019, the Health Ministry of India released about three commercials to promote oral contraceptives. In addition, various governments are selling contraceptive pills at pharmacy stores without doctor’s prescriptions, which is significantly contributing to the growth of the market.

The initiation of various family planning programmes and media campaigns to increase awareness regarding the importance and benefits of contraceptive drugs is augmenting the market growth. The redistribution of contraceptive services among health workers and pharmacy staff, among others, is increasing the accessibility of the underserved population of injectables and oral contractions. Hence, the increasing availability of diverse contraceptive drugs in developing countries is aiding the market growth. The development of new contraceptive technologies to boost the functionality and efficiency of contraceptive drugs is providing further impetus to the growth of the market.

 

Contraceptive Drugs: Market Segmentation

Contraceptive drugs, variously known as birth control drugs, are medicines that prevent unwanted pregnancies by releasing hormones like oestrogen and progesterone. They thicken mucus around the cervix to prevent ovulation. Contraceptive drugs are convenient to use and lower the risk of various health-related issues like breast cancer and polycystic ovary syndrome (PCOS), among others.

 

Global Contraceptive Drugs Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The major products of contraceptive drugs are:

  • Topical Contraceptives
  • Oral Contraceptive Pills
  • Injectable Contraceptives

The market can be broadly categorised on the basis of its age groups into:

  • 15-24 years
  • 25-34 years
  • 35-44 years
  • Above 44 years

Based on end-users, the market is divided into:

  • Homecare
  • Hospitals
  • Clinics

The EMR report looks into the regional markets of contraceptive drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Contraceptive Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Development of Contraceptive Drugs with Minimal Side Effects to Augment the Market Growth

The development of innovative contraceptive drugs to minimise the side-effects like nausea and vomiting is propelling the market growth. With the increasing attempts to boost the benefits of contraceptive drugs, new modes for their administration to enhance patient experience is surging, which is aiding the market growth. Furthermore, the increasing research activities to develop advanced contraceptive drugs is expected to propel the market growth. The rising acceptance of innovative contraceptive drugs like once-a-month pills to prevent ovulation or implantation is significantly contributing to the growth of the industry.

The increasing focus to provide innovative solutions for shared reproductive burden among both males and females is anticipated to drive the growth of the market. This is also leading to the initiation of various clinical trials of contraceptive drugs that stop sperm production to prevent unplanned pregnancies. As conventional contraceptive drugs result in side effects like nausea, vomiting, and mood swings, among others, long-acting reversible contraceptives are being developed, which is anticipated to bolster the industry growth. Moreover, increasing research activities to develop oestrogen-free drugs to lower failure rates as compared to oestrogen-based contraception is predicted to propel the market growth.

 

Key Industry Players in the Global Contraceptive Drugs Market

The report presents a detailed analysis of the following key players in the global contraceptive drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Piramal Enterprises Ltd.
  • Agile Therapeutics
  • Johnson & Johnson Services, Inc.
  • Abbive Inc.
  • Merck & Co Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Helm AG.
  • Reckitt Benckiser Group PLC
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Allergan plc.
  • Agile Therapeutics

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product Type
  • Route of Administration
  • Therapy Type
  • Age Group
  • Distribution Channel
  • Region
Breakup by Product Type
  • Contraceptive Drugs
    • Contraceptive Pills
    • Patch
    • Injectables
Breakup by Route of Administration
  • Oral
  • Parentals
  • Topicals
  • Others
Breakup by Therapy Type
  • Monotherapy
  • Combined Contraceptives
Breakup by Age Group
  • 15-45 Years
  • Above 45 Years
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channel
  • Public Channel
  • NGOs, Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Piramal Enterprises Ltd.
  • Agile Therapeutics
  • Johnson & Johnson Services, Inc.
  • Abbive Inc.
  • Merck & Co Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Helm AG.
  • Reckitt Benckiser Group PLC
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Allergan plc.
  • Agile Therapeutics

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Contraceptive Drugs Market Overview 

    3.1    Global Contraceptive Drugs Market Historical Value (2017-2023) 
    3.2    Global Contraceptive Drugs Market Forecast Value (2024-2032)
4    Global Contraceptive Drugs Market Landscape
    4.1    Global Contraceptive Drugs Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Contraceptive Drugs Product Landscape
        4.2.1    Analysis by Product Type
        4.2.2    Analysis by Route of Administration 
        4.2.3    Analysis by Age Group
        4.2.4    Analysis by Therapy Type
        4.2.5    Analysis by Distribution Channel
5    Global Contraceptive Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Contraceptive Drugs Market Segmentation 
    6.1    Global Contraceptive Drugs Market by Product Type
        6.1.1    Market Overview
        6.1.2    Contraceptive Drugs
            6.1.2.1    Contraceptive Pills
            6.1.2.2    Patch
            6.1.2.3    Injectables
    6.2    Global Contraceptive Drugs Market by Route of Administration
        6.2.1    Market Overview
        6.2.2    Oral
        6.2.3    Parentals
        6.2.4    Topicals
        6.2.5    Others
    6.3    Global Contraceptive Drugs Market by Therapy Type
        6.3.1    Market Overview
        6.3.2    Monotherapy
        6.3.3    Combined Contraceptives
    6.4    Global Contraceptive Drugs Market by Age Group
        6.4.1    Market Overview
        6.4.2    15-45 Years
        6.4.3    Above 45 Years
    6.5    Global Contraceptive Drugs Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Retail Pharmacy
        6.5.4    Clinics
        6.5.5    Online Channel
        6.5.6    Public Channel
        6.5.7    NGOs, Others
    6.6    Global Contraceptive Drugs Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Contraceptive Drugs Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Contraceptive Drugs Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Contraceptive Drugs Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Contraceptive Drugs Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Contraceptive Drugs Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Piramal Enterprises Ltd.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Agile Therapeutics
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Johnson & Johnson Services, Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Abbive Inc.
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Merck & Co Inc.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Teva Pharmaceuticals Industries Ltd.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Bayer AG
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Pfizer Inc.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Helm AG.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Reckitt Benckiser Group PLC 
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Viatris Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Amneal Pharmaceuticals LLC
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Bayer AG
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Allergan plc.
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Agile Therapeutics
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
18    Global Contraceptive Drugs Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global contraceptive drugs market attained a value of nearly USD 18.64 billion.

The market is projected to grow at a CAGR of 7% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 34.33 billion by 2032.

The market is being aided by the increasing availability of free and subsidised contraceptive drugs, the initiation of various family planning programmes and media campaigns, and the development of new contraceptive technologies.

The industry is expected to be augmented by the development of advanced contraceptive drugs, the rising acceptance of innovative contraceptive drugs, and the increasing clinical trials of contraceptive drugs for men.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major products of contraceptive drugs in the industry are topical contraceptives, oral contraceptive pills, and injectable contraceptives.

The significant age groups in the market are 15-24 years, 25-34 years, 35-44 years, and above 44 years.

The various end-users of contraceptive drugs are homecare, hospitals, and clinics.

The major players in the industry are Allergan plc, Johnson & Johnson, Bayer AG, Piramal Healthcare, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER